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CARD15/NOD2 encodes a protein involved in bacterial recognition by monocytes. Mutations in CARD15 have
recently been found in patients with Crohn disease (CD), a chronic inflammatory condition of the digestive tract.
Here, we report the mutational analyses of CARD15 in 453 patients with CD, including 166 sporadic and 287
familial cases, 159 patients with ulcerative colitis (UC), and 103 healthy control subjects. Of 67 sequence variations
identified, 9 had an allele frequency 15% in patients with CD. Six of them were considered to be polymorphisms,
and three (R702W, G908R, and 1007fs) were confirmed to be independently associated with susceptibility to CD.
Also considered as potential disease-causing mutations (DCMs) were 27 rare additional mutations. The three main
variants (R702W, G908R, and 1007fs) represented 32%, 18%, and 31%, respectively, of the total CD mutations,
whereas the total of the 27 rare mutations represented 19% of DCMs. Altogether, 93% of the mutations were
located in the distal third of the gene. No mutations were found to be associated with UC. In contrast, 50% of
patients with CD carried at least one DCM, including 17% who had a double mutation. This observation confirmed
the gene-dosage effect in CD. The patients with double-dose mutations were characterized by a younger age at
onset (16.9 years vs. 19.8 years; ), a more frequent stricturing phenotype (53% vs. 28%; ;Pp .01 Pp .00003
odds ratio 2.92), and a less frequent colonic involvement (43% vs. 62%; ; odds ratio 0.44) than werePp .003
seen in those patients who had no mutation. The severity of the disease and extraintestinal manifestations were
not different for any of the CARD15 genotypes. The proportion of familial and sporadic cases and the proportion
of patients with smoking habits were similar in the groups of patients with CD with or without mutation. These
findings provide tools for a DNA-based test of susceptibility and for genetic counseling in inflammatory bowel
disease.
Introduction
Crohn disease (CD [MIM 266600]) and ulcerative colitis
(UC [MIM 191390]) are classified as chronic idiopathic
inflammatory bowel diseases (IBDs). These two disorders
are usually easily differentiated. The inflammation in CD
may involve any segment of the digestive tract, from the
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mouth to the anus, and may affect the mucosa and the
deeper layers of the digestive wall. By contrast, UC lesions
are continuous and are restricted to the mucosa of the
large intestine, involving the rectum and a variable por-
tion of the colon (Podolsky 1991). In themajority of cases,
these characteristics permit a differential diagnosis be-
tween CD and UC in IBD, on the basis of clinical, en-
doscopic, and histological findings. However, in 10% of
cases, the classification of the IBD remains difficult, and
there is a need for additional diagnostic tools. Further-
more, even when a differential diagnosis is possible, the
age at onset, the extent of the disease, extraintestinalman-
ifestations, the natural course of the disease, and the re-
sponse to treatmentsmay define several clinical subgroups
846 Am. J. Hum. Genet. 70:845–857, 2002
of patients. These phenotypic variations suggest several
underlying etiological factors for IBD.
Despite numerous clinical and experimental studies,
the etiopathogenesis of IBD has remained largely un-
known. It is generally accepted that both CD and UC
are multifactorial diseases caused by the interplay of
genetic and environmental factors (Fiocchi 1998). Ep-
idemiological studies have suggested that various ex-
ogenous factors, such as infectious agents and cigarette
smoking, may contribute to the risk of being affected
with IBD (Hugot et al. 1999). In addition to environ-
mental factors, there is a strong genetic component in
IBD, as is illustrated by the high level of concordance
between identical twins combined with familial risk of
IBD (for review, see Hugot et al. 1999). Linkage studies
have revealed a number of putative IBD-susceptibility
loci, suggesting that several genes are involved in pre-
disposition to IBD (Hugot et al. 1996; Satsangi et al.
1996; Cho et al. 1998; Hampe et al. 1999; Ma et al.
1999; Duerr et al. 2000; Rioux et al. 2000; Vermeire
et al. 2001; Cavanaugh and The IBD International Ge-
netics Consortium 2001).
One of the genes causing susceptibility to CD was
recently identified as the CARD15/NOD2 gene (Ogura
et al. 2001a; Hugot et al. 2001). (The HUGO nomen-
clature committee recently proposed that the previous
NOD2/IBD1 gene name be changed to CARD15.)
CARD15 encodes a protein composed of two NH2-
terminal caspase recruitment domains (CARDs), a nu-
cleotide-binding domain (NBD), and 10 COOH-ter-
minal leucine-rich repeats (LRR) (Ogura et al. 2001b).
CARD15 is a member of the Ced4 superfamily, which
includes APAF-1 (Zou et al. 1997) and NOD1/CARD4
(Bertin et al. 1999; Inohara et al. 1999). The LRRs are
involved in the interaction with infecting bacterial li-
popolysaccharides (LPS), whereas the CARDs enable
the protein to induce apoptosis and the NF-kB signaling
pathways (Inohara et al. 2001). Thus, CARD15 has
been proposed to be an intracellular receptor for bac-
terial components in monocytes, where it is mainly ex-
pressed (Ogura et al. 2001b).
Three main mutations of CARD15, including a
frameshift mutation encoding a truncated protein
(1007fs), have been found in patients with CD but not
in patients with UC (Hampe et al. 2001; Hugot et al.
2001; Ogura et al. 2001a). These mutations occur in
the LRR domain or in its vicinity, suggesting that they
alter the recognition of the bacterial LPS. This hypoth-
esis has been supported by functional experiments per-
formed by Ogura et al. (2001a), who demonstrated that
the 1007fs mutation decreased the NF-kB activation by
the LPS. In addition to the three main mutations, we
were able to identify a large number of rare variants in
the gene (Hugot et al. 2001).
Here, we report in detail theCARD15mutations pre-
viously identified in series of 453 unrelated patients with
CD, 159 patients with UC, and 103 healthy control
subjects (Hugot et al. 2001). In addition, relationships
between genotype and phenotype—including age at
onset, disease location, severity of the disease, and
complications—are examined in the group of patients
with CD.
Subjects and Methods
Patients and Phenotype Recording
The patients in this study were recruited through a
large European consortium involving clinicians from
Belgium, Denmark, France, Germany, Ireland, Italy,
Spain, and Sweden. Homogeneous diagnostic criteria
based on clinical, endoscopic, radiological, and histo-
logical findings were used (Lennard-Jones 1989) and the
same clinical questionnaire was completed for each pa-
tient. This questionnaire included: date of birth, sex,
family history, age at onset, age at diagnosis, cigarette-
smoking habits (smoker/ex-smoker or nonsmoker), dis-
ease location at onset, disease location at its maximal
extent, granuloma, stenosis, transmural involvement, ex-
tradigestive symptoms, and therapeutic management.
Stenosis and transmural involvement were defined by
the occurrence, in the digestive tract, of at least one
stricture or by the presence of fistula or abscess, respec-
tively, as shown by radiological, endoscopic, or patho-
logical examinations during the evolution of the disease.
All patient data were recorded by a gastroenterologist.
A total of 453 unrelated patients with CD and 159
unrelated patients with UC were included in the study.
Among patients with CD, 166 had sporadic disease, and
287 were derived from multiplex families. The group of
patients with UC comprised 59 sporadic cases and 100
familial cases. The current average age at inclusion was
31.7 years (range 6–82 years) in the CD group and 34.5
years (range 6–85 years) in the UC group. Patients with
indeterminate colitis (IC) were excluded, as well as pa-
tients from “mixed” families in which cases of CD and
UC coexisted. As a control group, 103 unaffected white
individuals, including CEPH French family members
( ) and spouses of patients ( ), were alsonp 26 np 77
analyzed. This study was approved by the relevant local
ethics committees, and informed consent was obtained
from each of the participants.
Strategy Outline for Mutation Analysis
The 11 constant exons and all of the intron-exon junc-
tions of CARD15, corresponding to the previously pub-
lished sequence (GenBank accession numberAJ303140),
were first screened by direct sequencing of DNA from
51 patients with CD, 10 patients with UC, and 103
control subjects. To increase the chance to detect se-
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Table 1
Primers Used for Direct Sequencing and dHPLC Procedures Developed for CARD15 Screening
SCREENED
EXON
PRIMER
SIZE OF PCR
PRODUCT
(bp)Forward Reverse
2 ACCCTGCATCTGGCTTCTG CCTTTCCTGAGAACTCTGTG 555
3 ACATTGCTCCATCAGCCTTC GACTGCCCTTCCCTTTCTG 201
4a TGCCTCTTCTTCTGCCTTCC AGTAGAGTCCGCACAGAGAG 422
4b TTTCTCTTTGTCTTCCCATTC CCCTGTTCAGAGAAGCCC 380
4c GAAGTACATCCGCACCGAG AGCCAAGAGAAATGTCATCAG 446
4d ATGTGCTGCTACGTGTTCTC CAGACACCAGCGGGCACAG 456
4e ACCTTCAGATCACAGCAGCC GCTCCCCCATACCTGAAC 494
5 TTGTCTTACTAGCTCCATTTTC AGCCCATTGTCCACAGCC 162
6 CTGTTTGCATGATGGGGGG GGGAGATCACAGCATTAGAG 372
7 CGTCCCGCTGCCCCTTTC ACTCTCTCCCTGGCTTGTC 435
7dHPLC CCTGCCGCTGTGTTCTCTC TCAAAAGTCCCAAGCCCCTC 180
8 AAGTCTGTAATGTAAAGCCAC CCCAGCTCCTCCCTCTTC 380
9 CTTTCCCTGCTCTGACATAC CCCCAGAGCAGAGAATCC 156
10 GCTGCAATGGAGAGTGGG CTTTATTGGTTACCTTCACTTC 654
10dHPLC GTTCATCATCTTCCATAATCA AAAGGCCAGCAATTATTGTC 190
11 CTCACCATTGTATCTTCTTTTC GAATGTCAGAATCAGAAGGG 228
12 TAAAAACAGCCCTGACTTCC AAACTCACAGCCTGCTCAC 279
NOTE.—For exons 7 and 10, additional specific primers were designed for dHPLC analyses, as in-
dicated. Exon 4 was screened by amplification of five overlapping DNA fragments.
quence variations within this small group, patients with
CD were chosen within families whose affected siblings
were identical by descent at the IBD1 locus. A pair of
primers was designed for each exon, except for exon 4,
for which five overlapping fragments were amplified (ta-
ble 1). Mutations were then searched for in the remain-
ing patients. For the most polymorphic exons (number
2, 4, 6, 8, 9, and 11), the remaining patients with CD
or UC were studied by direct sequencing of one of the
DNA strands. In contrast, exons exhibiting little poly-
morphism in the initial screen (numbers 3, 5, 7, 10, and
12) were screened by a denaturing high-performance liq-
uid chromatography (dHPLC) procedure. When a var-
iation was observed in either the dHPLC profile or the
first strand sequence, the relevant PCR product was fur-
ther sequenced on both strands, to confirm the sequence
variation.
Direct Sequencing Analysis
DNA was isolated from peripheral blood leukocytes
by use of standard procedures. PCRs of CARD15 exons
were performed in a 50-ml volume containing 10 mM
Tris-HCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl2, 250
mM dNTPs, a 0.50 mM concentration of each primer,
200 ng of genomic DNA, and 2.5 U of AmpliTaq Gold
DNA polymerase (Perkin-Elmer Applied Biosystems).
For all fragments, cycling was performed with an initial
denaturation step of 10 min at 95C to activate Ampli-
Taq Gold, followed by 30 cycles of 94C for 30 s, 55C
for 30 s, and 72C for 30 s and a final extension step
of 72C for 10 min. Synthesis of appropriately sized PCR
products was confirmed by agarose gel electrophoresis.
PCR products used for sequencing analyses were purified
according to a solid phase reversible immobilization
(SPRI) protocol (Promega). Purified DNA products
(5–10 ng) were used in a cycle-sequencing reaction using
a Dye Terminator Cycle Sequencing Ready Reaction kit
(Perkin-Elmer Applied Biosystems), and fragments were
analyzed using an ABI 377 automated sequencer. Con-
trol subject and patient sequence data were aligned using
the Sequence Navigator analysis software, version 1.0.1
(Perkin-Elmer Applied Biosystems) and were compared
to the published CARD15 gene sequence. For homo-
geneity reasons, nucleotide numbering of CARD15 was
based on the largest sequence published by Ogura et al.
(2001b) (GenBank accession number AF178930), with
the first base of the ATG start codon being nucleotide
1.
dHPLC Experiments
Exons 3, 5, 7, 10, and 12 were screened for variations
by dHPLC (Liu et al. 1998). For exons 7 and 10, primers
different from those used for DNA sequencing were cho-
sen, to prevent intronic polymorphisms from interfering
with dHPLC analysis (table 1). For all five fragments,
PCR conditions were the same as described above.
Prior to dHPLC analysis, heteroduplex formationwas
induced by heat denaturation of PCR products at 98C
for 5 min, followed by a reannealing at 62C for 30 min.
Five microliters of these PCR products were then au-
tomatically loaded on the Hewlett-Packard ZORBAX
Eclipse column (Varian Instruments) and were eluted on
Table 2
CARD15 Variants Observed in 453 Patients with CD, 159 Patients with UC, and 103 Healthy Control Subjects
LOCATION AND
NUCLEOTIDE
CHANGE
PEPTIDE
CHANGE
POLYMORPHIC
MARKERa
PROTEIN
DOMAIN
NO (%) OF VARIANT ALLELES IN PATIENT GROUP
CD ( )np 906 UC ( )np 318 Control ( )np 206
Exon 2:
5′ UTR-37 TrG Unknown 2 1 0
5′ UTR-33 GrT Unknown 380 (42) 79 (25) 68 (33)
5′ UTR-15 TrA Unknown 1 0 1
315 GrA A105A CARD1 1 0 0
357 GrT L119L CARD1 1 0 0
413 GrA R138Q CARD2 1 0 0
418 GrA A140T CARD2 1 1 0
469 TrC W157R CARD2 1 0 0
534 CrG S178S CARD2 280 (31) 135 (42) 79 (38)
Exon 3:
566 CrT T189M CARD2 0 1 2
633 CrT A211A CARD2 0 1 0
Exon 4:
703 CrT R235C 1 0 0
743 TrG L248R 1 0 0
802 CrT P268S SNP5 375 (41) 77 (24) 57 (28)
866 ArG N289S NBD 6 0 3
871 GrA D291N NBD 1 0 0
881 CrG T294S NBD 1 0 0
902 CrT A301V NBD (P Loop) 1 0 0
931 CrT R311W NBD 2 1 0
1042 CrG L348V NBD 1 0 0
1055 ArG H352R NBD 2 0 0
1117 CrT R373C NBD 1 0 0
1241 ArG N414S NBD 1 0 0
1281 GrA P427P NBD 2 0 0
1292 CrT S431L NBD 1 0 0
1295 CrT A432V NBD 1 0 0
1321 GrA E441K NBD 1 0 0
1366 CrT L456L NBD 0 0 1
1377 CrT R459R SNP6 NBD 379 (42) 76 (24) 59 (29)
1509 GrA E503E NBD 0 1 0
1581 CrG P527P NBD 0 1 0
1671 delCCTGGG 558delLG NBD 1 0 0
1761 TrG R587R SNP7 301 (33) 142 (45) 83 (40)
1788 GrA T596T 1 0 0
1833 CrT A611A 3 6 5
1834 GrA A612T 1 0 0
1835 CrT A612V 2 0 0
2050 CrT R684W 1 0 0
2104 CrT R702W SNP8 98 (11) 10 (3) 9 (4)
2107 CrT R703C 11 1 0
2137 CrT R713C 1 0 0
2174 CrG A725G 3 0 0
2220 CrT I740I 1 0 0
2264 CrT A755V LRR1 11 1 0
2273 CrT A758V LRR1 1 0 0
2332 GrA E778K LRR2 3 0 0
2377 GrA V793M LRR2 4 0 0
IVS4:
IVS410 ArC Unknown 14 0 0
Exon 5:
2527 GrA E843K LRR4 1 0 0
Exon 6:
2558 ArG N853S LRR5 2 0 0
2587 ArG M863V LRR5 4 0 0
2619 CrT F873F LRR5 1 0 0
(continued)
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Table 2 (continued)
LOCATION AND
NUCLEOTIDE
CHANGE
PEPTIDE
CHANGE
POLYMORPHIC
MARKERa
PROTEIN
DOMAIN
NO (%) OF VARIANT ALLELES IN PATIENT GROUP
CD ( )np 906 UC ( )np 318 Control ( )np 206
IVS6:
IVS635 TrA Unknown 1 0 0
IVS7:
IVS7-5 TrC Unknown 1 0 0
Exon 7:
2656 GrA A885T LRR6 0 1 0
Exon 8:
2722 GrC G908R SNP12 LRR6 55 (6) 1 (.3) 2 (1)
2739 CrT D913D LRR7 1 0 0
2753 CrA A918D LRR7 8 0 1
2771 GrA G924D LRR7 1 0 0
Exon 9:
2817 TrC I939I LRR8 1 0 0
2863 GrA V955I LRR8 63 (7) 31 (10) 21 (10)
Exon 10:
2914 GrA V972I LRR9 1 0 0
2925 CrT L975L LRR9 0 2 0
2933 GrA G978E LRR9 1 0 0
Exon 11:
3020insC 1007fs SNP13 LRR10 96 (11) 4 (1) 4 (2)
IVS12:
IVS12-102 CrG Unknown 1 0 0
Exon 12:
3′ UTR 11 GrA Unknown 1 0 0
NOTE.—Variations were denoted according to the largest sequence reported by Ogura et al. (2001b). The A of the ATG
of the initiator Met codon was denoted as “nucleotide 1.” Probable DCMs are indicated in boldface italics.
a The correspondence with the polymorphic sites described elsewhere (Hugot et al. 2001) is indicated.
a linear acetonitrile gradient in a 0.1 M triethylamine
acetate buffer (TEAA), pH 7.0, with a constant flow rate
of 0.9 ml/min. The start and end points of the gradient
were adjusted according to the size of the PCR products.
Prior to sample analysis, restriction digests (pUC 18
HaeIII digest) were used at 50C to test the dHPLC
system and column performances and to give the ref-
erence by which to compare the size of DNA samples.
The denaturing run temperatures predicted by the
Stanford dHPLC Melt program were tested by running
a wild-type PCR product for each exon at the calculated
run temperature 2C. Experimental run temperatures
were as follows: 59C for exon 3; 59C and 60C for
exon 5; 61C and 62C for exon 7; 57C for exon 10;
and 60C and 61C for exon 12.
Data were acquired using an ultraviolet detector at
260 nm (UV-Vis prostar 310, Varian Instruments), and
heterozygous profiles were identified by visual inspection
of the chromatograms on the basis of the appearance of
superposed multiple eluting peaks. For each exon, het-
erozygous samples, when available, were used as internal
positive controls.
Statistical Analysis
Statistical comparisons were performed using the
STATVIEW version 4.51.1 package for Macintosh. x2
tests and ANOVA were used to compare qualitative and
quantitative variables between groups, respectively. Bon-
ferroni correction for multiple comparisons was applied
when necessary. A P value !.05 was considered signif-
icant. CIs for the odds ratios (OR) were calculated by
the logit method. Multivariate analysis was performed
using a logistic regression model to test the association
between phenotype variables and genotypes.
Results
Mutational Spectrum
All coding exons of CARD15, including the intron-
exon boundaries, were sequenced. In an initial screen—
performed on a sample of 51 patients with CD, 10 pa-
tients with UC, and 103 healthy control subjects—we
failed to detect frequent polymorphisms in exons 3, 5, 7,
10, and 12. We therefore developed a dHPLC procedure
to screen these exons, whereas the remaining exons were
studied by a direct sequence analysis strategy.
A total of 1,430 chromosomes from 453 patients with
CD, 159 patients with UC, and 103 healthy control sub-
jects were analyzed. We identified 67 sequence changes,
corresponding to an average of two intragenic altera-
tions per kilobase pair (table 2table 2). The sequence
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Figure 1 Distribution of the nine most frequent variants and the group of rare sequence variants observed in CARD15 gene in CD, UC,
and control populations. Allele frequencies of these variants in CD and UC populations were compared with those in the control group, and
the level of significance (P value) is denoted here by asterisks: *, ; **, ; ***, .P ! .05 P ! .005 P ! .0005
variations were evenly distributed along the gene. How-
ever, because of the large difference in size between the
exons, 150% (37/67) of these sequence changes occurred
in exon 4, which contains 1,816 bp. In contrast, no
variant was observed in the 70-bp coding region of exon
12.
Among the 67 sequence alterations, 8 were detected
in the noncoding regions of the gene (3′ and 5′ UTRs
and intervening sequences; table 2). Among these vari-
ants, the 5′ UTR-33 GrT alteration appeared to be more
frequent in CD than in control subjects ( ; fig. 1)Pp .02
and the IVS410 ArC intronic change was observed in
patients with CD only ( ).np 14
Except for the insertion frameshift mutation (1007fs)
and the 6-bp deletion (558delLG), the remaining vari-
ants (57/59) resulted in a single-base-pair substitution
(table 2). Of these, 47 were due to transition-type
changes, specifically the CrT transition ( ). Ofnp 23
the 57 point mutations, 43 (75%) affected a CpG di-
nucleotide, whereas the average GC content was 54.8%
(range 42.9%–64.3%) for the whole cDNA.
The definition of a “disease-causing” mutation
(DCM) is problematic when functional assays to deter-
mine the phenotypic effects of specific variants have not
been performed. To date, only the 1007fs variant has
been shown to be defective in activating the NF-kB path-
way (Ogura et al. 2001a). For the purposes of this study,
we considered that CARD15 sequence alterations that
led to a predicted premature truncation of the protein,
small deletions or insertions and nonconservative mis-
sense mutations were considered as potential DCMs
( ) (table 2). Sequence alterations occurring in thenp 31
noncoding sequence ( ) and silent ( ) or con-np 8 np 17
servative ( ) mutations were not considered path-np 11
ological (table 2).
CARD15 encodes a protein that contains two NH2-
terminal CARD domains, a centrally located NBD, and
10 COOH-terminal LRRs. Figure 2 shows the distri-
bution of DCMs along the protein and the number of
each identified DCM in the CD group. In the first CARD,
no DCM was observed. In the second CARD, four
DCMs (R138Q, A140T, W157R, and T189M) were
identified, which may affect the putative a helices H1
(R138Q and A140T), H2 (W157R), and H4 (T189M).
In the NBD, we observed eight DCMs and the conser-
vative mutation (A301V), which is located in the P-loop
box and thus may affect the function of the gene. Two
frequent DCMs (R702W and R703C) were located be-
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Figure 2 Distribution of the DCMs along the CARD15/NOD2
protein and number of mutated chromosomes observed among the
patients with CD. The asterisk (*) denotes that the P268S mutation
was not considered, because of its tight linkage disequilibrium with
other variants (see text).
tween the NBD and the LRR domains. Finally, 11 DCMs
were seen in the LRR domains, including the 2 frequent
mutations, G908R and 1007fs. Along the protein, the
proportion of DCMs per amino acid was 2% in the
CARD domains, 2.7% in the NBD, and 4% in the LRRs
(not significant). However, 93% of the mutated chro-
mosomes carried a DCM located in the distal third of
the gene (fig. 2).
Distribution of CARD15 Variants in Patients with CD,
Patients with UC, and Control Subjects
Nine sequence changes had an allele frequency of
15% in the CD group: 5′ UTR-33 GrT, S178S, P268S,
R459R, R587R, R702W, G908R, V955I, and 1007fs
(table 2). Figure 1 shows the frequencies of these nine
sequence changes in patients with CD, patients with UC,
and control subjects. No difference in allele frequency
was observed between UC and control subjects, except
for the 5′ UTR-33 GrT variant ( ). However, thisP ! .05
difference was not significant after the multiple com-
parisons were corrected for. In contrast, eight of the nine
variants had a significantly higher frequency in the CD
group compared with the control subjects, a result that
could be due to linkage disequilibrium between the al-
leles and CD.
Of these nine polymorphisms, only four can be con-
sidered DCMs according to the proposed definition (see
above). These sequence alterations were previously re-
ported as SNP5 (P268S), SNP8 (R702W), SNP12
(G908R), and SNP13 (1007fs) (dbSNP accessionnumbers
ss2978533, ss2978536, ss2978537, and ss2978539, re-
spectively) (Hugot et al. 2001). As previously reported,
the mutations R702W, G908R, and 1007fs were inde-
pendently associated with the CD phenotype ( ,Pp .005
, and , respectively).Pp .003 Pp .00009
The allele frequencies of the R702W, G908R, and
1007fs variants were, respectively, 0.09, 0.07, and 0.11
in cases of familial CD. In sporadic cases, the corre-
sponding frequencies were 0.14, 0.04, and 0.09. Con-
sidering that these three main mutations are independent
events (Hugot et al. 2001), the total frequency of the
mutated chromosomes is equal to the sum of the three
mutation frequencies. This sum (0.27) was identical in
familial and sporadic cases, suggesting that theCARD15
mutations have the same prevalence in sporadic and fa-
milial cases. Similarly, the frequencies of the three main
variants were identical in sporadic and familial cases of
UC (data not shown).
The P268S variant was also associated with CD
( ). However, previous studies demonstratedPp .0003
that this P268S variant occurs in phase with the R702W,
G908R, and 1007fs mutations (Hugot et al. 2001) and
that the association was related to this linkage disequi-
librium. For this reason, we considered this variant fur-
ther as a polymorphism. Similarly, the silent mutations
S178S, R459R, and R587R and the 5′ UTR-33 GrT
variant were found to be in linkage disequilibrium with
the three main variants and were not considered further
in the genotype-phenotype analyses. Lastly, the conser-
vative variant V955I was not associated with CD.
Rare sequence variants were observed in patients with
CD, patients with UC, and healthy control subjects (ta-
ble 2). These variations were more frequently encoun-
tered in CD (13% of CD chromosomes) than in control
subjects (6% of the control chromosomes) ( ).P ! .01
This association was independent of the three main
DCMs and the P268S variant, suggesting that at least
some of these rare variants are involved in the disease
predisposition (data not shown). However, for each var-
iant, the number of patients carrying the alternative al-
lele was too small to allow statistical calculations (table
2). In contrast, the rare sequence variations were not
associated with the UC phenotype (6% of the UC chro-
mosomes; ) (fig. 1).Pp .76
In the study population, 229 patients with CD (51%)
carried no DCMs in CARD15, 145 patients (32%) car-
ried one DCM, and 79 patients (17%) had two mutated
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Table 3
Number of Different Genotypes Observed in CD/UC/Control
Groups
VARIANT
NO. OF GENOTYPES
OBSERVED IN CD/UC/CONTROL GROUPS
R702W G908R 1007fs Rare DCMs Wild Type
R702W 11/1/0 10/0/0 15/0/0 8/0/0 43/8/9
G908R 2/0/0 11/0/0 2/0/0 28/1/2
1007fs 11/0/0 7/0/0 40/4/4
Rare DCMs 2/0/0 34/5/6
Wild type 229/141/82
NOTE.—Each cell of the table corresponds to the genotype com-
bining the two genetic variants indicated in the corresponding row
and column.
alleles, including 3 patients carrying three mutations.
Previous studies have shown that these mutations gen-
erally occur on separate chromosomes, so that individ-
uals in the latter group were further considered to have
mutations on both homologous chromosomes (Hugot
et al. 2001). This distribution was quite different from
that observed in UC and control subjects, showing a
large excess of individuals carrying two mutations
among patients with CD ( ) (table 3). It suggestsP ! .0001
a higher penetrance for susceptibility to CD among in-
dividuals with both mutated chromosomes. The small
excess of CD patients carrying a single mutation shows
that heterozygous individuals have a less marked risk of
developing the disease.
Genotype-Phenotype Correlations
We further examined the clinical manifestations in pa-
tients with CD according to their genotype. Because no
major difference was noted in either the clinical presen-
tation (data not shown) or allele frequencies (see above)
between sporadic and familial CD groups, all the CD
cases (sporadic or familial) were pooled for the geno-
type-phenotype analyses.
No phenotypic difference was observed between pa-
tients who were either (1) homozygous for one or (2)
compound heterozygous for any of the R702W, G908R,
and 1007fs mutations, suggesting that the respective
roles of these mutations are comparable (data not
shown). For DCMs, each private mutation was too rare
to allow statistical analyses. For these reasons, we pooled
frequent and rare mutations considered to be causative
of CD (i.e., the 31 above-mentioned DCMs, except for
the P268S variant; see above and table 2), and we di-
vided the 453 patients with CD into three distinct groups
defined by the number of DCMs carried (table 4). The
three groups correspond to normal homozygotes (G0),
heterozygotes for a normal and mutated sequence (G1),
and individuals with mutations in CARD15 on both
homologous chromosomes (G2), respectively. The fe-
male/male ratio was slightly higher in G1 than in G0
( after Bonferroni correction; not significant)Pp .05
and the average current age at inclusion was slightly
lower in G2 than in G0 (29.1 years vs. 32.5 years;
after Bonferroni correction; not significant).Pp .04
This second observation may be explained by a recruit-
ment bias related to the younger age at onset in G2 (see
below). The percentages of familial and sporadic cases
were identical in the three groups.
Patients carrying one or more CARD15 DCMs were
characterized by the development of stenoses during the
evolution of their disease, particularly in G2 patients,
presumed to have mutations on both chromosomes (G2
vs. G0: 53% vs. 28%; ; OR 2.92; 95% CIPp .00003
1.71–4.96). These comparisons remained significant af-
ter the Bonferroni correction for the multiple compari-
sons made ( ). Also in G2, the involvement of thenp 78
transverse colon, left colon, or rectum was significantly
less common at the onset of the disease (G2 vs. G0: 43%
vs. 62%; ; OR 0.44; 95% CI 0.26–0.74) andPp .003
during evolution (G2 vs. G0: 38% vs. 51%; ;Pp .04
OR 0.57; 95% CI 0.33–0.96). Finally, the age at onset
was, on average, slightly lower in G2 than in the two
other groups (G2 vs. G0: 16.9 vs. 19.8; ; andPp .01
G2 vs. G1: 16.9 vs. 20.0; ). As expected, con-Pp .02
cordant findings were observed regarding the age at di-
agnosis. It should be noted that the later reported as-
sociations were no longer significant after Bonferroni
correction ( ). Extraintestinal manifestations—in-np 78
cluding eye, skin, joint, and liver involvement—occurred
at similar rates within the three groups.
Because some of the phenotypic criteria studied here
may be linked (Polito et al. 1996), the relationships be-
tween all the phenotype variables and the genotype were
explored using a stepwise logistic regression. Three ex-
planatory variables remained independently associated
with having two mutations, the presence of stenosis
( ), the age at diagnosis ( ), and thePp .0007 Pp .0045
colorectal site as location at onset ( ). AfterPp .0094
these three variables were taken into account, the de-
velopment of granuloma also remained associated with
the presence of two mutations, but the statistical test
was of borderline significance ( ). No other var-Pp .07
iable adds information.
Regarding medical treatments, which were assumed
to be related to the severity of the disease, there was a
lower frequency of patients who had been treated at least
once with steroids among those bearing one or more
mutations when compared with patients having no mu-
tation (G1 vs. G0: 81% vs. 90%; ; G2 vs. G0:Pp .01
81% vs. 90%; ; OR 0.47; 95% CI 0.23–0.95).Pp .04
Surgical interventions tended to be more common in
group 2, but this did not achieve statistical significance
(G2 vs. G1: 63% vs. 52%; ). However, no sig-Pp .13
nificant difference between groups was observed for the
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Table 4
Genotype-Phenotype Relationships in Patients with CD
DETAILED PHENOTYPE All (n p 453)
VALUE FOR NO. OF DCMS COMPARISON (P)
0 ( )np 229 1 ( )np 145 2 ( )np 79 0 vs. 1 1 vs. 2 0 vs. 2
Sex (M/F) 45/55 48/52 38/62 49/51 .05 NS NS
Age at inclusion (years) 31.7 (6–82) 32.5 (7–82) 32.0 (6–65) 29.1 (12–61) NS NS .04
Familial/sporadic 63/37 60/40 68/32 64/36 NS NS NS
Age at onset (years) 19.4 (2–56) 19.8 (3–56) 20.0 (2–45) 16.9 (4–40) NS .02 .01
Age at diagnosis (years) 20.7 (3–61) 21.3 (3–61) 21.0 (3–54) 18.4 (5–42) NS .05 .03
Transmural involvement 41 38 44 46 NS NS NS
Stenosis 37 28 43 53 .002 NS .00003a
Granuloma 51 46 52 59 NS NS .04
Location at onset:
Ileon/right colon siteb 87 86 87 92 NS NS NS
Colorectal sitec 59 62 61 43 NS .008 .003
Upper digestive tractd 23 23 24 23 NS NS NS
Perineal lesions 31 28 35 30 NS NS NS
Maximal extent:
Ileon/right colon siteb 74 73 72 77 NS NS NS
Colorectal sitec 50 51 55 38 NS .01 .04
Upper digestive tractd 19 19 20 20 NS NS NS
Perineal lesions 29 28 32 27 NS NS NS
Extradigestive symptoms 34 32 39 29 NS NS NS
Eye 9 7 12 5 NS NS NS
Skin 12 12 12 15 NS NS NS
Joints 25 23 30 22 NS NS NS
Liver 2 3 1 1 NS NS NS
Medical management:e
Steroids 85 90 81 81 .01 NS .04
Azathioprine/6-
Mercaptopurine 41 46 36 36 NS NS NS
Nutritional supportf 39 36 40 43 NS NS NS
Surgery 55 55 52 63 NS NS NS
Other immunosuppressor/
anti-TNF antibodies 7 6 8 6 NS NS NS
Nonsmoker/smoker/ex-smoker 60/27/13 60/26/14 58/30/11 63/27/11 NS NS NS
NOTE.—Patients with CD were categorized according to the number of DCMs they carried (0, 1, or 2), and the phenotypes
were compared between groups. Quantitative traits are reported as mean (range). Qualitative traits are reported as % of patients.
Significant P values of the tests are indicated.
a after Bonferroni correction for the multiple comparisons ( ).P ! .005 np 78
b The ileocolonic site was defined by the involvement of the terminal ileum and/or the appendix and/or the right colon.
c Colonic site was defined by the involvement of the transverse colon and/or the left colon and/or the rectum.
d The upper digestive tract was defined by the involvement of at least one of the following sites: esophagus, stomach, duodenum,
jejunum, and proximal ileum.
e For medical management, patients were classified as positive if the corresponding treatment was used at least once during
the evolution of the disease.
f Nutritional support includes enteral and parenteral nutrition.
other treatments and for the cumulative number of med-
ications used (data not shown). Finally, differences in
smoking habits between the three groups were not sta-
tistically significant.
Because it is difficult to infer that the rare variants
play a role in CD predisposition without any functional
studies, we also performed the analyses after excluding
patients carrying a private mutation. No major differ-
ences were observed although thresholds of significance
were lower for the stricturing phenotype (G2 vs. G0:
57% vs. 28%; ; G1 vs. G0: 47% vs. 28%;Pp .00002
), the colorectal localization of the disease atPp .0004
onset (G2 vs. G0: 36% vs. 62%; ; G2 vs. G1:Pp .0003
36% vs. 59%; ). These findings may suggestPp .006
that some of the private mutations have a smaller bio-
logical effect than the three main variants.
A Genotyping Method for R702W, G908R, and 1007fs
Variants
A screening method for the presence of the recurrent
R702W, G908R, and 1007fs variants was developed in
the laboratory. A brief description of the method is given
below and in table 5, and more detailed explanations
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Table 5
Genotyping Procedures for the R702W, G908R, and 1007fs CD-Associated Variants
Mutation and
Genotyping Method Specific Primers
Size of the PCR Product
(bp)
R702W; allele-specifica SNP-specific primers: forward CCCACACTTAGCCTTGATG,
reverse wild type ATCTGAGAAGGCCCTGCTCT,
reverse mutated ATCTGAGAAGGCCCTGCTCC;
constant primers: forward TGAGGCAAAACAACTGAGAC,
reverse GCAGACATTGATTTTACACAG
439 (specific); 102 (control)
G908R; PCR-RFLPb Forward CCCAGCTCCTCCCTCTTC,
reverse AAGTCTGTAATGTAAAGCCAC
Wild type: 380; mutated: 138242
1007fs; PCR-product
sizingc
Forward Fam-GAATGTCAGAATCAGAAGGG,
reverse GCTCACCATTGTATCTTCTTTTC
Wild type: 230; mutated: 231
a PCR was performed using 40 mM of each specific primer and 20 mM of each constant primer at an annealing tempertature of 58C.
The PCR product was then loaded onto a 2% agarose gel.
b PCR products (annealing temperature 55C) were digested by HhaI enzyme and were loaded onto a 2% agarose gel.
c The fluorescently labeled PCR products (annealing temperature 55C) were loaded onto a polyacrylamide gel and were run on a
sequencer.
are available from the authors. The R702W mutation
is detected by an allele-specific PCR assay. The mutated
and wild-type alleles are independently amplified by use
of two different sets of primers. A nonpolymorphic frag-
ment is coamplified in the same tube as positive control
of DNA amplification. The G908R mutation is detected
by a restriction enzyme digestion of PCR-amplified
DNA, the sequence variation creating a novel Hha1 re-
striction enzyme site. Finally, the 1-bp insertion variant
(1007fs) genotyping is based on sizing of a labeled PCR
product after electrophoresis in an acrylamide gel. Our
method is based on fluorescently labeled primers and
automated sequencers. These genotyping methods have
proved, in our experience, to be robust, easy to perform,
and cost effective (data not shown).
Discussion
The recent identification of CARD15 as a gene involved
in susceptibility to CD (Hampe et al. 2001; Hugot et al.
2001; Ogura et al. 2001a) provides an opportunity to
study the relationships between CARD15 genotype and
phenotype in IBD. To address this question, we have per-
formed a comprehensive mutational analysis ofCARD15
in a European sample of 453 patients with CD, 159 in-
dividuals with UC, and 103 healthy control subjects.
Ogura et al. (2001b) reported two probableCARD15
isoforms, NOD2a and NOD2b, which are composed
of 12 and 11 exons, respectively. The first alternative
exon encodes a small 27–amino acid peptide without
any known functional domain. We have not observed
the NOD2a isoform in our studies (Hugot et al. 2001).
The cDNA that we have proposed elsewhere (GenBank
accession number AJ303140; Hugot et al. 2001) con-
tains a larger 5′ UTR than the sequence of Ogura et al.
(2001b). We have screened this 5′ UTR, the 11 common
exons, and the intron-exon boundaries of the gene.
However, to avoid heterogeneous annotations of mu-
tations, our observations are reported using the no-
menclature adopted by Ogura et al. (2001b) and, more
recently, by Hampe at al. (2001), who also used the
NOD2a isoform as the sequence reference (GenBank
accession number AF178930; Ogura et al. 2001b).
The mutation-screening method used in the present
study was not able to detect large DNA rearrangements,
nor did the analysis include the promoter or other po-
tential regulatory regions of the gene, all of which may
influence the expression of the gene. Despite these lim-
itations, we found a total of 67 different nucleotide
alterations in the affected individuals and control sub-
jects investigated. Of these alterations, 31were classified
as probable pathogenic mutations, including 29 mis-
sense mutations; a 1-bp insertion, leading to a frame-
shift that resulted in a truncated protein missing the last
33 amino acids; and an in-frame deletion of 6 bp. Of
the 29 observed substitutions, 23 were CrT transitions
found in CpG islands, which are known to be hotspots
for mutations (Cooper et al. 1995).
The other sequence alterations included eight changes
occurring in noncoding regions. Among these variants,
the 5′ UTR-33 GrT alteration appeared to be more
frequent in patients with CD than in control subjects
( ) and the IVS410 ArC intronic change wasPp .02
observed in patients with CD only ( ). These find-np 14
ings suggest that these two variants may play a role in
the CD predisposition. However, the consequences, at
the RNA level, of these variations were not examined.
Eleven conservative amino acid substitutions were also
identified, and functional assays will be required to es-
tablish or discard their role in CD pathogenesis. Finally,
17 additional silent variations were found.
Most of the 67 CARD15 variants identified so far are
rare. However, nine of them exhibited an allele frequency
10.05 in the group of patients with CD (5′ UTR-33 GrT,
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S178S, P268S, R459R, R587R, R702W, G908R, V955I,
and 1007fs). Of these nine variants, we confirmed that
R702W, G908R, and the frameshift mutation 1007fs
(elsewhere referred to as “R675W,” “G881R,” and
“980fs” [Hugot et al. 2001]) are significantly more fre-
quent among patients with CD (allele frequencies of
11%, 6%, and 11%, respectively) than in healthy control
subjects (4%, 1%, and 2%; , , andPp .005 Pp .003
, respectively). Similar results have been ob-Pp .00009
tained for the 1007fs variant by other investigators
(Hampe et al. 2001; Ogura et al. 2001a). The other fre-
quent variations were found to be in linkage disequilib-
rium with alleles in this group, and we considered them
to be polymorphisms. That assumption is even stronger
for the P268S variation, which was not significantly as-
sociated with the disease when tested alone (Hugot et al.
2001). However, functional studies will be required be-
fore definitively ruling out a role for the nonsilent vari-
ations P268S, V955I, and the 5′ UTR-33 GrT variant.
The group of the 58 rare variants was also associated
with the CD phenotype ( ), suggesting that atP ! .01
least some of them play a role in predisposition to CD.
Twenty-seven of them encoded either nonconservative
amino acid substitutions or a small deletion, including
20 mutations that were found exclusively or preferen-
tially in patients with CD, which also supports an as-
sociation with the CD phenotype. Because the number
of patients carrying each mutation was too small, this
question could not be resolved using statistical tests. On
the other hand, it is important to note that stronger
genotype-phenotype correlations were observed when
the patients with CD carrying one or more private mu-
tations were discarded from the analyses. The difference
suggests that some of these private mutations may have
a smaller biological effect than the three main variants.
Functional studies are now required to further investi-
gate this question.
CARD15 variations identified so far are evenly dis-
tributed along the entire coding sequence except in its
5′ portion encoding the first CARD domain. However,
the mutations located in the third distal of the coding
sequence are overrepresented in patients with CD (93%)
and correspond to the vast majority of disease-associ-
ated mutations encountered so far. This finding suggests
that the LRRs, which are known to interact with bac-
terial components, such as lipopolysaccharides (LPS),
and their adjacent region have an important role in CD
susceptibility. A reasonable hypothesis is that the mu-
tations associated with CD disrupt proper NF-kB or
apoptotic signaling, resulting in an inappropriatemono-
cyte response to bacterial infection.
The present results confirm the gene-dosage effect re-
ported elsewhere for the 1007fs (Hampe et al. 2001;
Ogura et al. 2001a) and the R702W and G908R mu-
tations (Hugot et al. 2001). These observations are now
extended to include the rare DCMs, and they demon-
strate that ∼50% of patients with CD carry at least one
mutation (vs. 20% in control subjects). Of these, 17%
(vs. 0% in control subjects) carry two mutations, which
are assumed to affect separate homologues. The latter
proportion is significantly higher than would be ex-
pected by chance ( ). This result suggests that aP ! .003
complete disruption of the NOD2-signaling pathway
may be necessary, in many cases, for development of
the disease.
No association was observed between any of the
CARD15 variants and the UC phenotype. As previously
mentioned, UC was not associated with the three main
CD-associated variations R702W, G908R, and 1007fs.
However, we also failed to identify any additional mu-
tations specifically involved in predisposition to UC, and
the overall rare variations were as frequent in the group
of patients with UC as in the group of healthy control
subjects ( ). These observations strongly suggestPp .76
that the role of CARD15 in UC is minimal or nonex-
istent. This is consistent with previous reports of no
linkage of the pericentromeric region of chromosome
16 to UC (Cavanaugh and The IBD International Ge-
netics Consortium 2001).
The detailed analyses of the genotype/phenotype re-
lationships did not allow us to find any specific group
of clinical features that were associated with particular
CARD15 mutations (data not shown). The effects of
the vast majority of DCMs seem to be roughly com-
parable. To see whether the presence of one or more
mutated copies of the CARD15 gene was associated
with a specific phenotypic outcome, we categorized pa-
tients with CD into three classes, according to the num-
ber of carried mutations. Patients bearing one or more
mutations developed significantly more stenoses of the
digestive tract. However, on the whole, patients bearing
only one mutation exhibited few other differences from
those bearing none of the identified mutations.
On the other hand, patients carrying two mutations
were characterized by a stricturing phenotype, a
younger age at onset, a less frequent involvement of the
left colon and rectum, and a more frequent formation
of granulomas. These variables were found to be in-
dependently associated with having two CARD15 mu-
tations. In other words and from the clinical point of
view, the association of a young age at onset, a purely
ileal involvement, and a stricturing phenotype charac-
terizes patients with a double-dose mutation. In con-
trast, this complete phenotypic association is observed
less often in patients with no or one mutation. Inter-
estingly, these findings suggest that patients having two
mutations resemble those initially reported by Crohn et
al. (1932), who defined the disease as a “regional en-
teritis” phenotype.
These phenotype-genotype correlations confirm the
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gene-dosage effect at the subphenotype level. The
younger age at onset is in accordance with the previously
reported higher linkage score on chromosome 16 when
patients diagnosed at an earlier age are analyzed (Brant
et al. 2000). However, the most significant result of these
genotype-phenotype analyses is that patients with
CARD15 mutations have a stricturing phenotype more
frequently than do patients carrying no mutations. This
is particularly true for patients with mutations on both
chromosomes, who have a threefold higher risk of de-
veloping a stenosis than do patients with no mutations.
This difference may be useful in clinical classification and
management of the patients. However, prospective clin-
ical studies are now needed to confirm the prognostic
value of CARD15 genotyping. No difference was ob-
served among the three genotype groups for the severity
of the disease (as estimated by the need for medication
and surgery) or in the extradigestive manifestations.
The allele frequency of the three main variants is com-
parable in familial and sporadic cases, and the propor-
tion of familial to sporadic cases is identical in the three
groups of patients defined by the number of carried
mutations. Therefore, mutations in CARD15 could not
be invoked to explain the small clinical differences ob-
served between these two categories of patients (Col-
ombel et al. 1996; Lee and Lennard-Jones 1996; Polito
et al. 1996). Finally, smoking habits were similar be-
tween groups, suggesting that additional independent
genetic factors may interact with this environmental risk
factor (Tobin et al. 1987; Cosnes et al. 1996).
This study also proposes a practical approach for
CARD15 genotyping. Confirming that the variants
R702W, G908R, and 1007fs are themost important ones
for the phenotype classification and that they represent
81% of the mutated alleles, we propose that initial ge-
notyping efforts should be focused on these three poly-
morphisms. A rapid and efficient procedure is reported
here, based respectively on allele-specific PCR, PCR-
RFLP, and PCR product–sizing methods. This procedure
is easily implemented in laboratories involved in molec-
ular biology. In case of a negative result, this study also
provides the basis for the detection of rarer mutations,
suggesting that the ends of exon 4, exon 8, and exon
6—which carry the other most frequent mutations—
should be screened first.
In addition to endoscopic, radiological, and histolog-
ical analyses, CARD15 genotyping may represent an
additional tool for the clinician in his (her) clinical prac-
tice and research. This study helps to define the limits
of the usefulness of CARD15 genotyping. However, ad-
ditional clinical studies are now necessary for deter-
mination of which clinical situations CARD15-based
tests may be the most relevant and cost effective for
patients and researchers.
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